LINERMEDA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 199,692 | 246,556 | 364,836 | 623,617 | 689,219 | 746,424 | 744,271 |
| Profit before tax | 66,036 | 104,043 | 148,208 | 307,324 | 320,478 | 295,300 | 276,843 |
| Net profit | 63,615 | 101,480 | 146,743 | 305,441 | 317,236 | 292,478 | 232,548 |
| Equity | 129,067 | 170,546 | 307,815 | 433,256 | 450,492 | 392,970 | 305,518 |
| Liabilities | 5,390 | 4,133 | 9,312 | 7,264 | 11,612 | 12,932 | 50,900 |
| Non-current assets | 55,797 | 53,112 | 77,643 | 72,753 | 79,837 | 79,150 | 80,779 |
| Current assets | 78,028 | 121,567 | 239,484 | 367,767 | 382,267 | 326,752 | 275,639 |
| Total assets | 133,825 | 174,679 | 317,127 | 440,520 | 462,104 | 405,902 | 356,418 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 107,180 | 128,112 | 127,998 |
| Social insurance contributions | - | - | - | - | 69,972 | 86,610 | 91,283 |
|
Financial indicators
|
|||||||
| Revenue change y/y | +10.3% | +23.5% | - | +70.9% | +10.5% | +8.3% | -0.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 47.5% | 58.1% | 46.3% | 69.3% | 68.7% | 72.1% | 65.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 49.3% | 59.5% | 47.7% | 70.5% | 70.4% | 74.4% | 76.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 31.9% | 41.2% | 40.2% | 49.0% | 46.0% | 39.2% | 31.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 33.1% | 42.2% | 40.6% | 49.3% | 46.5% | 39.6% | 37.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 18,433 | 23,669 | 31,050 | 44,544 | 45,443 | 43,907 | 42,128 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LINERMEDA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-10-18 | 2021-10-27 | 102.52 |
| 2021-09-16 | 2021-09-21 | 17.02 |
LINERMEDA - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company LINERMEDA is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-06-18 | 2026-09-02 | 0.83 |
| 2026-04-14 | 2026-04-20 | 1.95 |
| 2026-04-01 | 2026-04-13 | 581.74 |
| 2026-03-29 | 2026-03-31 | 11545.14 |
| 2025-06-19 | 2025-07-01 | 15.86 |
| 2025-02-20 | 2025-03-10 | 5.66 |
| 2024-09-19 | 2025-01-01 | 6.06 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LINERMEDA, UAB (code 157033280) is a Private Limited Liability Company operating in general medical practice activities. In 2025, the company generated revenue of €744.3K and net profit of €232.5K, with a profit margin of 31.2%. Revenue was broadly stable compared with 2024, showing a slight year-on-year decline of 0.3%, while 2-year revenue growth remained positive at 8.0%. Profitability softened over the period: net profit fell from €317.2K in 2023 to €292.5K in 2024 and €232.5K in 2025, alongside a declining margin from 46.0% to 39.2% and then 31.2%. At the same time, the balance sheet became smaller, with total assets decreasing from €462.1K in 2023 to €356.4K in 2025. Equity stood at €305.5K and liabilities at €50.9K in 2025, giving an equity ratio of 85.7% and a debt-to-equity ratio of 0.17. Asset turnover was 2.09x, and revenue per employee was €43.8K.